Stock listing

Hyloris Pharmaceuticals Sa

Selected listing: A2P7Y0 · LS · EUR · DE

Hyloris Pharmaceuticals Sa (Lang & Schwarz: A2P7Y0), Health Technology. Latest release Sep 28, 2026: Consolidated 2026 Half-Year Report: Hyloris Delivers 56%…

A2P7Y0:LSEURDEUpdated October 3, 2026

Ticker: Lang & Schwarz: A2P7Y0
Asset type: Stock
Sector: Health Technology
Industry: Pharmaceuticals: Major
Exchange: Lang & Schwarz
Currency: EUR

Latest news from Hyloris Pharmaceuticals Sa

Consolidated 2026 Half-Year Report: Hyloris Delivers 56% Revenue Growth and Its Lowest Half-Year Net Loss Since IPO, Advances Its Mavericks, Core Drivers and Promising Seeds

September 28, 2026

Hyloris Pharmaceuticals : Regulated Information Hyloris’ Annual General Shareholders Meeting on June 9, 2026 ENGLISH VERSION

May 8, 2026

Hyloris Pharmaceuticals : Regulated Information Hyloris releases Annual Report 2025 ENGLISH VERSION

April 30, 2026

Consolidated Results 2025 - Hyloris Achieves Strong Royalty Growth and Portfolio Expansion with Solid Cash Position: a year of bold moves and breakthrough milestones

March 26, 2026

Hyloris Pharmaceuticals : Inside Information Hyloris Provides Update on FDA Review of Valacyclovir for Oral Suspension ENGLISH VERSION

February 19, 2026

All Hyloris Pharmaceuticals Sa news →

Research Hyloris Pharmaceuticals Sa

Hyloris Pharmaceuticals Sa company profile

View the public company page for Hyloris Pharmaceuticals Sa on 6ix.

Hyloris Pharmaceuticals Sa news

Read company news and market updates connected to Hyloris Pharmaceuticals Sa.

Hyloris Pharmaceuticals Sa investor events

Find investor webinars, events, and replay context for Hyloris Pharmaceuticals Sa.